Mostrar o rexistro simple do ítem

dc.contributor.authorDomínguez-González, C.
dc.contributor.authorDíaz-Marín, C.
dc.contributor.authorJuntas-Morales, R.
dc.contributor.authorNascimiento-Osorio, A.
dc.contributor.authorRivera Gallego, Alberto 
dc.contributor.authorDíaz-Manera, J.
dc.date.accessioned2025-08-26T10:55:47Z
dc.date.available2025-08-26T10:55:47Z
dc.date.issued2022
dc.identifier.citationDomínguez-González C, Díaz-Marín C, Juntas-Morales R, Nascimiento-Osorio A, Rivera-Gallego A, Díaz-Manera J. Survey on the management of Pompe disease in routine clinical practice in Spain. Orphanet Journal of Rare Diseases. 2022;17(1).
dc.identifier.issn1750-1172
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/639e3275fe5bc92de889d638*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20749
dc.description.abstractBackground: Despite the availability of several clinical guidelines, not all health professionals use their recommendations to manage patients with Pompe disease, a rare genetic disorder involving high-impact therapy. Through several discussion meetings and a survey, the present study aimed to learn about the management of Pompe disease in routine clinical practice in Spain, to improve clinical care in a real-life situation. Results: The survey was sent to 42 healthcare professionals who manage patients with Pompe disease in their clinical practice. Although most respondents followed the clinical guidelines, clinical practice differed from the expert recommendations in many cases. Approximately 7% did not request a genetic study to confirm the diagnosis before starting treatment, and 21% considered that only two dried blood spot determinations suffice to establish the diagnosis. About 76% requested anti-GAA antibodies when there is a suspicion of lack of treatment efficacy, though a significant percentage of respondents have never requested such antibodies. According to 31% of the respondents, significant impairment of motor function and/or respiratory insufficiency is a requirement for authorizing medication at their hospital. Up to 26% waited for improvements over the clinical follow-up to maintain treatment and withdrew it in the absence of improvement since they did not consider disease stabilization to be a satisfactory outcome. Conclusions: The results highlight the lack of experience and/or knowledge of some professionals caring for patients with Pompe disease. It is necessary to develop and disseminate simple guidelines that help to apply the expert recommendations better or centralize patient follow-up in highly specialized centers.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleSurvey on the management of Pompe disease in routine clinical practice in Spain*
dc.typeArticleen
dc.authorsophosDomínguez-González, J. C.
dc.authorsophosDíaz-Marín, C.
dc.authorsophosJuntas-Morales, R.
dc.authorsophosNascimiento-Osorio, A.
dc.authorsophosRivera-Gallego, A.
dc.authorsophosDíaz, Manera
dc.identifier.doi10.1186/s13023-022-02574-5
dc.identifier.sophos639e3275fe5bc92de889d638
dc.issue.number1
dc.journal.titleOrphanet Journal of Rare Diseases*
dc.relation.publisherversionhttps://ojrd.biomedcentral.com/counter/pdf/10.1186/s13023-022-02574-5;https://ojrd.biomedcentral.com/counter/pdf/10.1186/s13023-022-02574-5.pdfes
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Vigoes
dc.subject.keywordCHUVIes
dc.subject.keywordIISGSes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number17


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Atribución 4.0 Internacional
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAtribución 4.0 Internacional